DOT1L and chronic myelogenous leukemia, BCR-ABL1 positive: BAZ1A, BAZ2B, CHAF1A, DOT1L, JMJD1C and miR612 epigenetic regulators were selected from those 200 genes that showed the greatest difference in expression levels in the case of comparing imatinib-treated and untreated CML cells.